Respiratory Infections 2019
DOI: 10.1183/13993003.congress-2019.oa4944
|View full text |Cite
|
Sign up to set email alerts
|

Late Breaking Abstract - Airway hyperresponsiveness in bronchiectasis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…de Koning Gans et al . [ 25 ] presented preliminary data from the screening of FORZA (formoterol-beclamethasone in patients with bronchiectasis) study. The preliminary data of 23 patients showed airway hyperresponsiveness (AHR) in 35% i.e., eight patients in non-CF bronchiectasis, excluding patients with a history of asthma or COPD.…”
Section: Discussionmentioning
confidence: 99%
“…de Koning Gans et al . [ 25 ] presented preliminary data from the screening of FORZA (formoterol-beclamethasone in patients with bronchiectasis) study. The preliminary data of 23 patients showed airway hyperresponsiveness (AHR) in 35% i.e., eight patients in non-CF bronchiectasis, excluding patients with a history of asthma or COPD.…”
Section: Discussionmentioning
confidence: 99%
“…It is hypothetically possible that the presence of recurrent infections, with the resulting inflammatory state and oxidative stress [22], could cause a reduction in number [23] and/or a dysfunction of β 2 -adrenoceptors [24] in the lungs, and, simultaneously, induce a hyperresponsiveness of the pulmonary muscarinic receptor system [25] in bronchiectasis patients.…”
mentioning
confidence: 99%